Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. · 1995
Read Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. by Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. (1995) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2033628.txt.
Introduction
Pyrhönen and colleagues ran a randomised trial in 1995 for stomach cancer that could not be removed by surgery. Forty-one patients received either a three-drug chemotherapy mix, called FEMTX, or supportive care alone. Both groups also got vitamins A and E. The trial ran from 1986 to 1992. Chemotherapy combined fluorouracil, epidoxorubicin and methotrexate in repeated cycles.
Six of 21 treated patients responded, a rate of 29 percent, including four complete responses. No control patient responded, and 80 percent worsened. Time before the cancer grew was 5.4 months with chemotherapy, against 1.7 months without, and median survival was 12.3 months against 3.1 months, a clear gain. Severe side effects were common, especially low white cell counts, but only one possible treatment death occurred.
Catalog record
| CREATOR | Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. |
|---|---|
| YEAR | 1995 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. By S. Pyrhönen, T. Kuitunen, P. Nyandoto, M. Kouri Published in: British Journal of Cancer DOI: 10.1038/bjc.1995.114 ABSTRACT A phase III randomised study, comparing treatment with fluorouracil, epidoxorubicin and methotrexate (FEMTX) with the best supportive care, was conducted in patients with unresectable or metastatic gastric cancer. During the period from July 1986 to June 1992, 41 patients were randomised to receive FEMTX or best supportive care. MTX was given in a dose of 1500 mg m-2 intravenously (i.v.) followed after 1 h by 5-FU 1500 mg m-2 i.v. on day 1; leucovorin rescue was started after 24 h (30 mg orally every 6 h for 48 h) and epidoxorubicin 60 mg m-2 i.v. was administered on day 15. In addition both groups received tablets containing vitamins A and E. Response rates for FEMTX were as follows: complete response (CR), 19% (4/21); partial response (PR), 10% (2/21); no change (NC), 33% (7/21); and progressive disease (PD), 24% (5/21). Response rates in the control group were: NC, 20% (4/20); and PD, 80% (16/20). Increased pain was observed in one patient in the treated group and in 11 patients in the control group within the first 2 months. WHO grade III/IV toxicity in the chemotherapy group was as follows: nausea/vomiting 40%, diarrhoea 10%, stomatitis 15%, leucopenia 50% and thrombocytopenia 10%. One possible treatment-related death was due to sepsis. The median time to progression in the FEMTX group was 5.4 months [95% confidence interval (CI) 3.1-11.7 months], but only 1.7 months in the control group (95% CI 1.2-2.7 months) (P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI 1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment, giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival. It can be used as a reference treatment in testing new investigational combinations. Brilish dJm o C w (15) 71, 587-591 ? 1995 Stockton Press AJI nghts reserved 000740920/95 $9.00 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer S Pyrhonen', T Kuitunen', P Nyandotol and M Kouri' Departments of 'Radiotherapy and Oncology and 'Clinical Pharmacology, Helsinki University Central Hospital, Helsinki, Finland. Smimary A phase III randomised study, comparing treatment with fluorouracil. epidoxorubicin and methotrexate (FEMTX) with the best cupportive care, was conducted in patients with unresectable or metastatic gastric cancer. During the period from July 1986 to June 1992, 41 patients were randomised to receive FEMTX or best supportive care. MTX was given in a dose of 1500mgm-2 intravenously (i.v.) followed after 1 h by 5-FU 1500 mg m- 2 i.v. on day 1; leucovorin rescue was started after 24 h (30 mg orally every 6 h for 48 h) and epidoxorubicin 60 mg m- 2 i.v. was administered on day 15. In addition both groups received tablets containing vitamins A and E. Response rates for FEMTX were as follows: complete response (CR), 19% (4/21); partial response (PR), 10% (2j21); no change (NC), 33% (7'21); and progressive disease (PD). 24% (5'21). Response rates in the control group were: NC, 20% (4/20); and PD, 80% (16 20). Increased pain was observed in one patient in the treated group and in 11 patients in the control group within the first 2 months. WHO grade HI/IV toxicity in the chemotherapy group was as follows: nausea/vomiting 40%, diarrhoea 10%, stomatitis 15%, leucopenia 50% and thrombocytopenia 10%. One possible treatment-related death was due to sepsis. The median time to progression in the FEMTX group was 5.4 months [95% confidence interval (CI) 3.1-11.7 months], but only 1.7 months in the control group (95% CI 1.2-2.7 months) (P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI 1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment, giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival. It can be used as a reference treatment in testing new investigational combinations. Keywords chemotherapy; gastric cancer; survival Treatment of gastric cancer remains a great challenge. At diagnosis, 75% of patients have disseminated disease (Dupont et al., 1978). Even among the subgroup of patients able to undergo potentially curative resection, relapse is com- mon. Because 5 year survival ranges from 10% to 15% of all patients with newly diagnosed disease, the use of chemo- therapy in patients with gastric cancer has been the subject of great interest. At present, four drugs have been identified as exhibiting modest or moderate single-agent activity in patients with advanced gastric cancer. These drugs are 5-fluorouracil (5- FU), adriamycin, mitomycin and cisplatin. During the late 1970s a FAM (fluorouracil, adriamycin, mitomycin) regimen composed of these active drugs was widely adapted as a routine treatment for advanced gastric cancer, although no controlled trials supported its routine use. In fact, in a com- parative study between 5-FU and 5-FU plus adriamycin or FAM, no difference in survival between the treatment groups was observed (Cullinan et al., 1985). During the last decade a new, promising cancer regimen has been reported using the technique of biochemical modu- lation of 5-FU. Klein et al. (1983) developed the regimen of high-dose methotrexate (MTX), high-dose 5-FU and adria- mycin with leucovorin rescue, called FAMTX. The first report on this combination described a response rate as high as 63% (Klein et al., 1983). Since then, in different studies, a total of 364 patients have received FAMT`X, with a cumula- tive response rate of 41% (Kelsen et al., 1992). Although the response rates using these new drug com- binations are considerably higher than with 5-FU alone, no definitive proof exists as to whether these treatments have any real impact on patients' survival, nor does there exist any Correspondence: S Pyrh6nen. Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland Received 1 July 1993; revised 12 September 1994; accepted 10 October 1994 such study on 5-FU. To elucidate this issue, we performed a randomised tnral in which patients were assigned to receive either chemotherapy (FEMTX) plus trace amounts of vitamin A and E or the same vitamins and best supportive care only. In this study we replaced adriamycin with epi- rubicin for reasons discussed later. The main focus of this study was to analyse whether this chemotherapy regimen can change the natural course of advanced gastric cancer, thus prolonging patients' survival. Patients and methods Patients During the period from July 1986 to June 1992, 41 patients with histologically confirmed gastric cancer were entered into this study. During the study period five other patients were eligible for this study but refused to take part in the ran- domisation. The patients were randomised by a sealed envelope method. Random permutated blocks (length 10) were used. The block was not known by